Drugs / SGN-STNV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04665921 | Jan 2021 → Mar 2024 | Her2-receptor negative breast cancer, endometrium neoplasm, exocrine pancreatic carcinoma, gastric neoplasm +6 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-STNV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04665921 ↗ |
| Route | Intravenous | “Given into the vein (IV; intravenously)” NCT04665921 ↗ |